Contraindicated (one)bortezomib will improve the stage or influence of mavacamten by influencing hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or average CYP2C19 inhibitors may possibly enhance mavacamten systemic publicity, causing heart failure as a result of systolic dysfunction.Lab and/or medical exams (for instance finish blood de